Skip to main content
. 2018 Aug 9;109(9):2852–2862. doi: 10.1111/cas.13724

Figure 3.

Figure 3

Pharmacokinetic profile of ASP8273 in Phase I (dose escalation) and Phase II (dose expansion). A, Single‐dose ASP8273 plasma concentration (phase I). B, Repeat‐dose ASP8273 plasma concentration (phase I). C, Single‐dose ASP8273 plasma concentration (phase II). D, Repeat‐dose ASP8273 plasma concentration (phase II)